In mice eating a fatty diet, a drug called GW501516 seems to turn on a chain reaction in the liver that helps burn fat more efficiently.

Pro

Against

Evidence from Studies

Supporting (1)

Community contributions welcome

The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

Cross-Sectional Study

Animal

2011 May

Contradicting (0)

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Source Study

The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

Score: 12

DOI: 10.1210/en.2010-1468

Similar Assertions

In mice on a high-fat diet, a drug called GW501516 might help liver cells better manage fat by turning up a key protein and activating a fat-burning switch.

93%

In mice on a high-fat diet, a drug called GW501516 might boost a specific fat in the liver that could help turn on a fat-burning switch, making the body burn fat more efficiently.

88%

In mice eating a bad diet, a drug called GW501516 might help keep a key energy-sensing switch in the liver working properly, which could help their bodies handle the stress of unhealthy eating.

81%

In mice eating a high-fat diet, taking a drug called GW501516 seems to boost a substance in their blood that shows their liver is burning more fat for energy.

77%